Artivion (NYSE:AORT) SVP Sells $910,820.70 in Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 44,001 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. The trade was a 42.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Artivion Trading Up 3.3%

NYSE AORT traded up $0.66 during mid-day trading on Monday, hitting $20.76. The company’s stock had a trading volume of 300,307 shares, compared to its average volume of 531,476. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25. The stock’s fifty day simple moving average is $28.92 and its two-hundred day simple moving average is $36.98. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. The firm has a market capitalization of $1.01 billion, a P/E ratio of 86.42 and a beta of 1.27.

Institutional Trading of Artivion

A number of hedge funds have recently made changes to their positions in the company. Verition Fund Management LLC raised its stake in shares of Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after purchasing an additional 274 shares during the period. Entropy Technologies LP grew its position in shares of Artivion by 6.0% during the fourth quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after buying an additional 310 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Artivion by 6.2% during the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock worth $349,000 after buying an additional 477 shares in the last quarter. Finally, Arizona State Retirement System grew its position in shares of Artivion by 4.6% during the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock worth $512,000 after buying an additional 494 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AORT. Weiss Ratings lowered shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Citizens Jmp dropped their price objective on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Friday, April 10th. Needham & Company LLC dropped their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Artivion currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.17.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.